In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention |
| |
Authors: | Aaron E. Brice Gabriel A. Hernandez Mariluz Sanchez Marshall Haynick Cesar E. Mendoza |
| |
Affiliation: | Division of Cardiology, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL, USA |
| |
Abstract: | Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker has been proven to reduce subsequent cardiovascular events and in-stent thrombosis in patients undergoing percutaneous coronary intervention. Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents. Currently, there are no evidence-based guidelines to aid clinicians when switching between P2Y12 receptor blockers. Here we describe two patients that developed in-stent thrombosis when switching from ticagrelor to clopidogrel using a 300 mg clopidogrel loading dose. Both patients presented with ST elevation myocardial infarction and underwent stent placement but then developed in-stent thrombosis 48 hours after switching from ticagrelor to clopidogrel. These cases illustrate the severe consequences of suboptimal platelet inhibition and the need for prospective trials thoroughly powered to assess clinical outcomes in order to determine the most appropriate strategy when switching from ticagrelor to clopidogrel. |
| |
Keywords: | Clopidogrel loading dose percutaneous coronary intervention stent thrombosis switching ticagrelor |
|